Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Primary Health Care | 23 | 2024 | 294 | 4.870 |
Why?
|
Family Practice | 11 | 2024 | 49 | 3.470 |
Why?
|
Manitoba | 46 | 2024 | 48 | 3.420 |
Why?
|
Canada | 33 | 2024 | 130 | 2.920 |
Why?
|
Gonorrhea | 7 | 2017 | 24 | 2.420 |
Why?
|
Healthcare Disparities | 8 | 2021 | 494 | 1.980 |
Why?
|
Humans | 139 | 2024 | 37093 | 1.890 |
Why?
|
Chronic Disease | 6 | 2021 | 484 | 1.790 |
Why?
|
Mental Disorders | 7 | 2021 | 309 | 1.710 |
Why?
|
Income | 7 | 2023 | 140 | 1.620 |
Why?
|
Female | 93 | 2024 | 20969 | 1.510 |
Why?
|
Indians, North American | 3 | 2019 | 159 | 1.470 |
Why?
|
Adult | 66 | 2024 | 11712 | 1.460 |
Why?
|
Middle Aged | 62 | 2024 | 10129 | 1.440 |
Why?
|
Prenatal Care | 3 | 2021 | 73 | 1.430 |
Why?
|
Leptospirosis | 7 | 2012 | 25 | 1.400 |
Why?
|
Hospitalization | 8 | 2021 | 388 | 1.390 |
Why?
|
Male | 86 | 2024 | 20025 | 1.380 |
Why?
|
Retrospective Studies | 33 | 2024 | 2026 | 1.340 |
Why?
|
Physicians, Family | 6 | 2023 | 22 | 1.330 |
Why?
|
Aged | 46 | 2024 | 6741 | 1.300 |
Why?
|
Anti-Bacterial Agents | 4 | 2017 | 352 | 1.290 |
Why?
|
Health Services, Indigenous | 2 | 2019 | 24 | 1.280 |
Why?
|
Delivery of Health Care | 8 | 2024 | 276 | 1.260 |
Why?
|
Reimbursement, Incentive | 2 | 2018 | 11 | 1.170 |
Why?
|
Young Adult | 34 | 2024 | 4268 | 1.160 |
Why?
|
Neisseria gonorrhoeae | 3 | 2017 | 15 | 1.120 |
Why?
|
Population Surveillance | 11 | 2021 | 238 | 1.070 |
Why?
|
Adolescent | 35 | 2024 | 5363 | 1.050 |
Why?
|
Hawaii | 26 | 2020 | 1929 | 1.040 |
Why?
|
Azithromycin | 2 | 2017 | 6 | 1.020 |
Why?
|
Child | 25 | 2024 | 3131 | 1.020 |
Why?
|
Leptospira | 6 | 2012 | 22 | 1.010 |
Why?
|
Mental Health Services | 3 | 2020 | 118 | 1.010 |
Why?
|
Ambulatory Care | 3 | 2021 | 75 | 0.980 |
Why?
|
Internship and Residency | 2 | 2024 | 125 | 0.930 |
Why?
|
Health Services Accessibility | 6 | 2024 | 560 | 0.920 |
Why?
|
Infant | 17 | 2024 | 1046 | 0.910 |
Why?
|
Syphilis | 2 | 2016 | 23 | 0.910 |
Why?
|
Quality of Health Care | 3 | 2022 | 138 | 0.900 |
Why?
|
Cardiovascular Diseases | 7 | 2024 | 664 | 0.890 |
Why?
|
Child, Preschool | 19 | 2024 | 1418 | 0.880 |
Why?
|
Prescriptions | 1 | 2022 | 18 | 0.840 |
Why?
|
Bioterrorism | 3 | 2006 | 20 | 0.840 |
Why?
|
Vaccination | 5 | 2024 | 288 | 0.820 |
Why?
|
Electronic Health Records | 3 | 2017 | 66 | 0.820 |
Why?
|
Influenza, Human | 4 | 2021 | 83 | 0.810 |
Why?
|
Physicians | 6 | 2019 | 163 | 0.790 |
Why?
|
Health Status Indicators | 1 | 2021 | 75 | 0.790 |
Why?
|
Pregnancy Outcome | 3 | 2021 | 87 | 0.790 |
Why?
|
Aged, 80 and over | 16 | 2021 | 2379 | 0.750 |
Why?
|
Cohort Studies | 18 | 2023 | 1492 | 0.740 |
Why?
|
Hospitals | 2 | 2020 | 86 | 0.740 |
Why?
|
Poverty | 3 | 2023 | 348 | 0.730 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 197 | 0.720 |
Why?
|
Mothers | 2 | 2019 | 181 | 0.710 |
Why?
|
Comorbidity | 10 | 2021 | 623 | 0.710 |
Why?
|
Chlamydia Infections | 3 | 2009 | 196 | 0.700 |
Why?
|
Infant, Newborn | 10 | 2024 | 894 | 0.670 |
Why?
|
Health Policy | 3 | 2019 | 165 | 0.650 |
Why?
|
Multiple Sclerosis | 4 | 2021 | 45 | 0.640 |
Why?
|
Fractures, Comminuted | 1 | 2018 | 1 | 0.630 |
Why?
|
Wrist Joint | 1 | 2018 | 2 | 0.630 |
Why?
|
Radius Fractures | 1 | 2018 | 3 | 0.630 |
Why?
|
Radiography | 1 | 2018 | 72 | 0.620 |
Why?
|
Community Health Services | 1 | 2019 | 185 | 0.620 |
Why?
|
Quality Indicators, Health Care | 1 | 2018 | 40 | 0.620 |
Why?
|
Osteoporosis | 1 | 2018 | 34 | 0.620 |
Why?
|
Ceftriaxone | 1 | 2017 | 7 | 0.610 |
Why?
|
Inflammatory Bowel Diseases | 4 | 2021 | 92 | 0.610 |
Why?
|
Pelvic Inflammatory Disease | 2 | 2015 | 19 | 0.610 |
Why?
|
Contact Tracing | 1 | 2017 | 19 | 0.610 |
Why?
|
Holistic Health | 1 | 2017 | 13 | 0.600 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2017 | 30 | 0.600 |
Why?
|
Forms and Records Control | 1 | 2017 | 5 | 0.600 |
Why?
|
Psychotropic Drugs | 1 | 2017 | 12 | 0.600 |
Why?
|
Prevalence | 12 | 2021 | 1455 | 0.590 |
Why?
|
Mass Screening | 4 | 2017 | 462 | 0.590 |
Why?
|
Pediatrics | 2 | 2021 | 68 | 0.580 |
Why?
|
Pregnancy Complications | 2 | 2017 | 126 | 0.580 |
Why?
|
Diabetes Mellitus | 4 | 2014 | 485 | 0.560 |
Why?
|
Cross-Sectional Studies | 12 | 2024 | 2721 | 0.560 |
Why?
|
Attitude of Health Personnel | 7 | 2020 | 198 | 0.560 |
Why?
|
Radiosurgery | 2 | 2014 | 51 | 0.560 |
Why?
|
Mammography | 2 | 2017 | 188 | 0.540 |
Why?
|
Arthritis, Rheumatoid | 3 | 2021 | 43 | 0.530 |
Why?
|
Referral and Consultation | 2 | 2014 | 117 | 0.530 |
Why?
|
Disaster Planning | 2 | 2006 | 52 | 0.520 |
Why?
|
Cause of Death | 3 | 2020 | 156 | 0.520 |
Why?
|
Patient-Centered Care | 4 | 2022 | 63 | 0.520 |
Why?
|
Pregnancy | 10 | 2023 | 1549 | 0.510 |
Why?
|
Ontario | 9 | 2023 | 30 | 0.500 |
Why?
|
Socioeconomic Factors | 11 | 2022 | 1067 | 0.500 |
Why?
|
Regional Health Planning | 2 | 2004 | 14 | 0.490 |
Why?
|
Specialization | 1 | 2014 | 21 | 0.490 |
Why?
|
Battered Women | 1 | 2014 | 10 | 0.490 |
Why?
|
Drug Resistance, Bacterial | 2 | 2012 | 77 | 0.490 |
Why?
|
Societies, Medical | 1 | 2014 | 66 | 0.480 |
Why?
|
Sexually Transmitted Diseases | 2 | 2016 | 164 | 0.480 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 2 | 0.480 |
Why?
|
Data Collection | 2 | 2014 | 194 | 0.470 |
Why?
|
Practice Guidelines as Topic | 4 | 2019 | 191 | 0.470 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2013 | 19 | 0.460 |
Why?
|
Coffee | 1 | 2013 | 20 | 0.460 |
Why?
|
Needs Assessment | 4 | 2020 | 170 | 0.450 |
Why?
|
Heart Failure | 5 | 2024 | 235 | 0.450 |
Why?
|
Preventive Health Services | 2 | 2023 | 64 | 0.450 |
Why?
|
Health Care Surveys | 5 | 2017 | 136 | 0.450 |
Why?
|
Health Surveys | 3 | 2009 | 373 | 0.450 |
Why?
|
Violence | 1 | 2014 | 134 | 0.440 |
Why?
|
Health Knowledge, Attitudes, Practice | 7 | 2015 | 864 | 0.440 |
Why?
|
Neoplasms | 3 | 2012 | 1103 | 0.440 |
Why?
|
Carcinoma | 1 | 2014 | 96 | 0.440 |
Why?
|
Clinical Competence | 3 | 2018 | 130 | 0.440 |
Why?
|
Biomedical Research | 2 | 2024 | 400 | 0.430 |
Why?
|
Prostatic Neoplasms | 3 | 2014 | 935 | 0.430 |
Why?
|
Breast Feeding | 4 | 2021 | 113 | 0.430 |
Why?
|
Myocardial Ischemia | 3 | 2019 | 75 | 0.430 |
Why?
|
Interpersonal Relations | 1 | 2014 | 205 | 0.430 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 160 | 0.420 |
Why?
|
Risk Factors | 13 | 2023 | 3562 | 0.420 |
Why?
|
Hepatitis C | 1 | 2013 | 125 | 0.420 |
Why?
|
Depressive Disorder | 3 | 2018 | 174 | 0.410 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 149 | 0.410 |
Why?
|
Pneumonia, Viral | 1 | 2013 | 76 | 0.410 |
Why?
|
Urethritis | 1 | 2011 | 2 | 0.400 |
Why?
|
Diagnostic Errors | 1 | 2011 | 20 | 0.390 |
Why?
|
Neisseria meningitidis | 1 | 2011 | 16 | 0.390 |
Why?
|
Incidence | 10 | 2021 | 922 | 0.380 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 77 | 0.380 |
Why?
|
Disease Outbreaks | 4 | 2011 | 155 | 0.370 |
Why?
|
Anxiety Disorders | 3 | 2018 | 309 | 0.360 |
Why?
|
Health Promotion | 5 | 2023 | 653 | 0.360 |
Why?
|
Erectile Dysfunction | 1 | 2010 | 38 | 0.350 |
Why?
|
Registries | 2 | 2017 | 335 | 0.340 |
Why?
|
Appendicitis | 1 | 2008 | 17 | 0.330 |
Why?
|
Heterosexuality | 1 | 2009 | 88 | 0.330 |
Why?
|
Rheumatic Fever | 2 | 2018 | 13 | 0.320 |
Why?
|
Quality of Life | 2 | 2024 | 481 | 0.310 |
Why?
|
Child Welfare | 3 | 2017 | 42 | 0.310 |
Why?
|
Bipolar Disorder | 2 | 2018 | 43 | 0.310 |
Why?
|
Hormone Replacement Therapy | 1 | 2007 | 41 | 0.300 |
Why?
|
Occupational Exposure | 3 | 2019 | 79 | 0.300 |
Why?
|
HIV Infections | 3 | 2018 | 2303 | 0.300 |
Why?
|
Urban Population | 4 | 2014 | 333 | 0.290 |
Why?
|
Breast Neoplasms | 2 | 2017 | 1502 | 0.290 |
Why?
|
Emergency Service, Hospital | 2 | 2020 | 208 | 0.290 |
Why?
|
Influenza Vaccines | 2 | 2021 | 55 | 0.290 |
Why?
|
Testosterone | 1 | 2007 | 193 | 0.280 |
Why?
|
Dentists | 1 | 2006 | 10 | 0.280 |
Why?
|
Nurses | 1 | 2006 | 48 | 0.280 |
Why?
|
Health Status Disparities | 4 | 2018 | 642 | 0.280 |
Why?
|
Health Status | 4 | 2017 | 380 | 0.270 |
Why?
|
Prostate | 1 | 2007 | 154 | 0.270 |
Why?
|
Child Abuse | 2 | 2017 | 79 | 0.270 |
Why?
|
Education, Veterinary | 1 | 2006 | 3 | 0.270 |
Why?
|
Risk Assessment | 4 | 2023 | 753 | 0.270 |
Why?
|
Myocardial Infarction | 3 | 2024 | 225 | 0.270 |
Why?
|
Regression Analysis | 2 | 2017 | 455 | 0.270 |
Why?
|
Educational Status | 3 | 2022 | 313 | 0.270 |
Why?
|
Treatment Outcome | 4 | 2020 | 1369 | 0.270 |
Why?
|
Age Factors | 6 | 2017 | 1033 | 0.260 |
Why?
|
Telemedicine | 2 | 2022 | 182 | 0.260 |
Why?
|
Public Housing | 2 | 2015 | 15 | 0.250 |
Why?
|
Interprofessional Relations | 3 | 2021 | 54 | 0.250 |
Why?
|
Neoplasm Metastasis | 1 | 2006 | 219 | 0.250 |
Why?
|
Follow-Up Studies | 7 | 2023 | 974 | 0.250 |
Why?
|
Colorectal Neoplasms | 4 | 2012 | 441 | 0.240 |
Why?
|
Coronary Angiography | 3 | 2020 | 90 | 0.240 |
Why?
|
Journal Impact Factor | 1 | 2024 | 2 | 0.240 |
Why?
|
Demography | 2 | 2022 | 175 | 0.240 |
Why?
|
Microbial Sensitivity Tests | 2 | 2017 | 201 | 0.240 |
Why?
|
Juvenile Delinquency | 1 | 2004 | 44 | 0.240 |
Why?
|
Diabetic Angiopathies | 1 | 2023 | 21 | 0.230 |
Why?
|
Predictive Value of Tests | 2 | 2005 | 400 | 0.230 |
Why?
|
Medication Adherence | 2 | 2022 | 179 | 0.220 |
Why?
|
Occult Blood | 3 | 2012 | 29 | 0.220 |
Why?
|
Prisoners | 1 | 2004 | 83 | 0.220 |
Why?
|
Stroke | 2 | 2024 | 286 | 0.220 |
Why?
|
Nurse Practitioners | 1 | 2002 | 14 | 0.210 |
Why?
|
Schools | 2 | 2022 | 260 | 0.210 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 448 | 0.210 |
Why?
|
Social Class | 2 | 2014 | 247 | 0.210 |
Why?
|
Seasons | 2 | 2014 | 112 | 0.210 |
Why?
|
Patient Compliance | 3 | 2012 | 212 | 0.210 |
Why?
|
False Positive Reactions | 2 | 2016 | 26 | 0.210 |
Why?
|
Infant, Low Birth Weight | 2 | 2021 | 39 | 0.200 |
Why?
|
Health Care Costs | 2 | 2020 | 77 | 0.200 |
Why?
|
Residence Characteristics | 2 | 2015 | 322 | 0.200 |
Why?
|
Morphine | 1 | 2022 | 85 | 0.200 |
Why?
|
Liver Neoplasms | 3 | 2012 | 190 | 0.200 |
Why?
|
Physician-Patient Relations | 4 | 2017 | 128 | 0.200 |
Why?
|
Brachial Plexus | 1 | 2021 | 3 | 0.200 |
Why?
|
Birth Injuries | 1 | 2021 | 9 | 0.200 |
Why?
|
Patient Care Team | 2 | 2018 | 47 | 0.190 |
Why?
|
Prognosis | 6 | 2023 | 739 | 0.190 |
Why?
|
Health Resources | 1 | 2021 | 32 | 0.190 |
Why?
|
Hypospadias | 1 | 2020 | 3 | 0.190 |
Why?
|
Patient Care Management | 1 | 2020 | 6 | 0.190 |
Why?
|
Technology Assessment, Biomedical | 1 | 2020 | 7 | 0.180 |
Why?
|
Qualitative Research | 2 | 2020 | 446 | 0.180 |
Why?
|
Community Health Planning | 1 | 2020 | 35 | 0.180 |
Why?
|
Hyperbaric Oxygenation | 1 | 2020 | 33 | 0.180 |
Why?
|
British Columbia | 4 | 2023 | 10 | 0.180 |
Why?
|
Agricultural Workers' Diseases | 1 | 2019 | 5 | 0.180 |
Why?
|
Linear Models | 2 | 2018 | 275 | 0.180 |
Why?
|
Occupational Health | 1 | 2019 | 29 | 0.170 |
Why?
|
Office Visits | 3 | 2021 | 22 | 0.170 |
Why?
|
Education, Distance | 1 | 2020 | 44 | 0.170 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 1 | 0.170 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 52 | 0.170 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 284 | 0.170 |
Why?
|
Health Personnel | 2 | 2018 | 228 | 0.170 |
Why?
|
Social Responsibility | 1 | 2019 | 14 | 0.170 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 69 | 0.170 |
Why?
|
Coronary Artery Disease | 1 | 2020 | 142 | 0.170 |
Why?
|
Pesticides | 1 | 2019 | 52 | 0.170 |
Why?
|
Program Evaluation | 2 | 2017 | 339 | 0.170 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 62 | 0.170 |
Why?
|
Research Personnel | 2 | 2024 | 155 | 0.170 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 2 | 2012 | 7 | 0.160 |
Why?
|
Databases, Factual | 3 | 2021 | 291 | 0.160 |
Why?
|
Continuity of Patient Care | 2 | 2022 | 94 | 0.160 |
Why?
|
Crowding | 1 | 2018 | 4 | 0.160 |
Why?
|
Triage | 1 | 2018 | 26 | 0.160 |
Why?
|
Israel | 1 | 2018 | 19 | 0.160 |
Why?
|
Waiting Lists | 1 | 2018 | 36 | 0.160 |
Why?
|
Age Distribution | 4 | 2021 | 225 | 0.160 |
Why?
|
Cost of Illness | 1 | 2018 | 76 | 0.150 |
Why?
|
Databases as Topic | 1 | 2017 | 20 | 0.150 |
Why?
|
Geriatrics | 1 | 2018 | 57 | 0.150 |
Why?
|
Ciprofloxacin | 1 | 2017 | 14 | 0.150 |
Why?
|
Penicillins | 1 | 2017 | 12 | 0.150 |
Why?
|
Postnatal Care | 1 | 2017 | 13 | 0.150 |
Why?
|
Tetracycline | 1 | 2017 | 17 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2017 | 38 | 0.150 |
Why?
|
beta-Lactamases | 1 | 2017 | 33 | 0.150 |
Why?
|
Immunization | 1 | 2017 | 92 | 0.150 |
Why?
|
Immune System Diseases | 1 | 2017 | 21 | 0.150 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 148 | 0.150 |
Why?
|
House Calls | 1 | 2017 | 9 | 0.150 |
Why?
|
Health Services Needs and Demand | 2 | 2012 | 146 | 0.150 |
Why?
|
Respiratory Tract Diseases | 2 | 2014 | 23 | 0.150 |
Why?
|
Primary Prevention | 1 | 2017 | 59 | 0.150 |
Why?
|
Family Therapy | 1 | 2017 | 21 | 0.150 |
Why?
|
Risk | 2 | 2018 | 267 | 0.150 |
Why?
|
Computers | 1 | 2017 | 35 | 0.150 |
Why?
|
Micronesia | 2 | 2009 | 80 | 0.150 |
Why?
|
Syphilis Serodiagnosis | 1 | 2016 | 6 | 0.150 |
Why?
|
Injections, Intramuscular | 1 | 2016 | 20 | 0.150 |
Why?
|
Cooperative Behavior | 1 | 2018 | 219 | 0.140 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 227 | 0.140 |
Why?
|
Adolescent Health Services | 1 | 2017 | 29 | 0.140 |
Why?
|
Immunoenzyme Techniques | 1 | 2016 | 108 | 0.140 |
Why?
|
Premature Birth | 1 | 2018 | 75 | 0.140 |
Why?
|
Child Health Services | 1 | 2017 | 43 | 0.140 |
Why?
|
Suicide | 1 | 2018 | 118 | 0.140 |
Why?
|
Multivariate Analysis | 3 | 2017 | 583 | 0.140 |
Why?
|
Competency-Based Education | 1 | 2016 | 10 | 0.140 |
Why?
|
Logistic Models | 5 | 2017 | 923 | 0.140 |
Why?
|
Cholesterol | 2 | 2010 | 205 | 0.140 |
Why?
|
Whole-Body Irradiation | 2 | 2006 | 9 | 0.140 |
Why?
|
Stereotaxic Techniques | 2 | 2006 | 20 | 0.140 |
Why?
|
Child Development | 1 | 2017 | 88 | 0.140 |
Why?
|
Pregnancy in Adolescence | 1 | 2016 | 32 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 643 | 0.140 |
Why?
|
Lipids | 1 | 2017 | 235 | 0.140 |
Why?
|
Internet | 1 | 2017 | 211 | 0.140 |
Why?
|
Disease Notification | 1 | 2015 | 6 | 0.130 |
Why?
|
Rural Population | 3 | 2021 | 294 | 0.130 |
Why?
|
Odds Ratio | 1 | 2017 | 534 | 0.130 |
Why?
|
United States | 5 | 2019 | 4223 | 0.130 |
Why?
|
Decision Making | 1 | 2017 | 203 | 0.130 |
Why?
|
Organization and Administration | 1 | 2014 | 1 | 0.120 |
Why?
|
Airway Obstruction | 1 | 2014 | 9 | 0.120 |
Why?
|
Indonesia | 1 | 2014 | 12 | 0.120 |
Why?
|
Guidelines as Topic | 2 | 2012 | 54 | 0.120 |
Why?
|
Research Support as Topic | 1 | 2014 | 80 | 0.120 |
Why?
|
Health Services Research | 1 | 2015 | 148 | 0.120 |
Why?
|
Sentinel Surveillance | 1 | 2014 | 21 | 0.120 |
Why?
|
Guideline Adherence | 2 | 2012 | 84 | 0.120 |
Why?
|
Mood Disorders | 1 | 2014 | 48 | 0.120 |
Why?
|
Insurance, Health | 1 | 2014 | 126 | 0.110 |
Why?
|
Community Health Centers | 1 | 2013 | 45 | 0.110 |
Why?
|
Biliary Tract Surgical Procedures | 1 | 2013 | 1 | 0.110 |
Why?
|
Gallbladder | 1 | 2013 | 3 | 0.110 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 282 | 0.110 |
Why?
|
Gallbladder Diseases | 1 | 2013 | 3 | 0.110 |
Why?
|
Education, Medical | 1 | 2014 | 104 | 0.110 |
Why?
|
Sex Factors | 2 | 2013 | 898 | 0.110 |
Why?
|
Survival Rate | 4 | 2018 | 311 | 0.110 |
Why?
|
Research | 1 | 2014 | 163 | 0.110 |
Why?
|
Analysis of Variance | 1 | 2014 | 550 | 0.110 |
Why?
|
Inflammation | 1 | 2017 | 618 | 0.110 |
Why?
|
Zoonoses | 1 | 2012 | 17 | 0.110 |
Why?
|
Sexual Behavior | 3 | 2016 | 609 | 0.110 |
Why?
|
Cholangiocarcinoma | 1 | 2012 | 6 | 0.100 |
Why?
|
Population Growth | 1 | 2012 | 8 | 0.100 |
Why?
|
Mammals | 1 | 2012 | 105 | 0.100 |
Why?
|
Lung Neoplasms | 2 | 2006 | 358 | 0.100 |
Why?
|
Meningococcal Infections | 1 | 2011 | 3 | 0.100 |
Why?
|
Forecasting | 1 | 2012 | 128 | 0.100 |
Why?
|
Culture Media | 1 | 2011 | 90 | 0.100 |
Why?
|
Algorithms | 1 | 2014 | 465 | 0.100 |
Why?
|
Smoking | 1 | 2018 | 940 | 0.100 |
Why?
|
Recreation | 1 | 2011 | 32 | 0.100 |
Why?
|
Models, Statistical | 1 | 2012 | 180 | 0.090 |
Why?
|
Family | 1 | 2012 | 173 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2012 | 215 | 0.090 |
Why?
|
Professional Autonomy | 1 | 2010 | 4 | 0.090 |
Why?
|
Nursing Staff | 1 | 2010 | 7 | 0.090 |
Why?
|
Public Health | 2 | 2017 | 372 | 0.090 |
Why?
|
Impotence, Vasculogenic | 1 | 2010 | 13 | 0.090 |
Why?
|
Carbolines | 1 | 2010 | 15 | 0.090 |
Why?
|
Nurse's Role | 1 | 2010 | 31 | 0.090 |
Why?
|
Triazines | 1 | 2010 | 20 | 0.090 |
Why?
|
Purines | 1 | 2010 | 38 | 0.090 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2010 | 34 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2012 | 145 | 0.090 |
Why?
|
Reproducibility of Results | 2 | 2003 | 935 | 0.090 |
Why?
|
Sulfones | 1 | 2010 | 44 | 0.090 |
Why?
|
Student Health Services | 1 | 2009 | 11 | 0.090 |
Why?
|
Contraception, Postcoital | 1 | 2009 | 8 | 0.090 |
Why?
|
Imidazoles | 1 | 2010 | 126 | 0.090 |
Why?
|
Agglutination Tests | 2 | 2012 | 5 | 0.080 |
Why?
|
Piperazines | 1 | 2010 | 111 | 0.080 |
Why?
|
Health Planning Guidelines | 2 | 2009 | 8 | 0.080 |
Why?
|
Prostate-Specific Antigen | 2 | 2007 | 118 | 0.080 |
Why?
|
Statistics, Nonparametric | 2 | 2006 | 108 | 0.080 |
Why?
|
Rupture, Spontaneous | 1 | 2008 | 6 | 0.080 |
Why?
|
Appendectomy | 1 | 2008 | 16 | 0.080 |
Why?
|
Hospitals, Pediatric | 1 | 2008 | 20 | 0.080 |
Why?
|
Asthma | 1 | 2013 | 380 | 0.080 |
Why?
|
Mortality | 2 | 2020 | 145 | 0.080 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 441 | 0.080 |
Why?
|
Focus Groups | 2 | 2017 | 348 | 0.080 |
Why?
|
Research Design | 3 | 2017 | 313 | 0.080 |
Why?
|
Drug Utilization | 1 | 2007 | 29 | 0.080 |
Why?
|
Blood Chemical Analysis | 1 | 2007 | 21 | 0.080 |
Why?
|
Blood Glucose | 1 | 2010 | 353 | 0.080 |
Why?
|
Severity of Illness Index | 1 | 2010 | 610 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2007 | 38 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2007 | 41 | 0.070 |
Why?
|
Hypertension | 1 | 2014 | 796 | 0.070 |
Why?
|
Prospective Studies | 2 | 2024 | 1378 | 0.070 |
Why?
|
Dengue | 1 | 2008 | 94 | 0.070 |
Why?
|
Motor Activity | 1 | 2009 | 418 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2006 | 22 | 0.070 |
Why?
|
Time Factors | 3 | 2021 | 1742 | 0.070 |
Why?
|
Professional Role | 1 | 2006 | 40 | 0.070 |
Why?
|
Morbidity | 2 | 2018 | 91 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2006 | 45 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2006 | 275 | 0.060 |
Why?
|
Psychiatry | 1 | 2005 | 27 | 0.060 |
Why?
|
Lipoproteins | 1 | 2005 | 64 | 0.060 |
Why?
|
Triglycerides | 1 | 2005 | 138 | 0.060 |
Why?
|
Brain Neoplasms | 1 | 2006 | 111 | 0.060 |
Why?
|
Epidemiologic Research Design | 1 | 2004 | 16 | 0.060 |
Why?
|
Workload | 1 | 2004 | 22 | 0.060 |
Why?
|
Public Health Administration | 1 | 2004 | 26 | 0.060 |
Why?
|
Social Perception | 1 | 2005 | 62 | 0.060 |
Why?
|
Public Opinion | 1 | 2024 | 17 | 0.060 |
Why?
|
Pacific Islands | 1 | 2004 | 119 | 0.060 |
Why?
|
Bacteriological Techniques | 1 | 2004 | 14 | 0.060 |
Why?
|
Bibliometrics | 1 | 2024 | 17 | 0.060 |
Why?
|
Coronary Disease | 1 | 2005 | 124 | 0.060 |
Why?
|
Censuses | 1 | 2004 | 24 | 0.060 |
Why?
|
Developing Countries | 1 | 2004 | 99 | 0.060 |
Why?
|
Clinical Laboratory Techniques | 1 | 2004 | 26 | 0.060 |
Why?
|
Meconium | 1 | 2003 | 10 | 0.060 |
Why?
|
Nova Scotia | 1 | 2023 | 4 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 1 | 2004 | 47 | 0.060 |
Why?
|
Maternal-Fetal Exchange | 1 | 2003 | 29 | 0.060 |
Why?
|
Medically Underserved Area | 1 | 2004 | 104 | 0.060 |
Why?
|
Serotyping | 1 | 2003 | 36 | 0.060 |
Why?
|
Women's Health | 1 | 2004 | 145 | 0.060 |
Why?
|
Cotinine | 1 | 2003 | 43 | 0.060 |
Why?
|
Disease Progression | 1 | 2006 | 601 | 0.060 |
Why?
|
Epidemiologic Studies | 1 | 2003 | 31 | 0.060 |
Why?
|
Serologic Tests | 1 | 2003 | 43 | 0.050 |
Why?
|
Physician-Nurse Relations | 1 | 2002 | 3 | 0.050 |
Why?
|
Neuropsychological Tests | 1 | 2023 | 259 | 0.050 |
Why?
|
Fatty Acids | 1 | 2003 | 127 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2003 | 217 | 0.050 |
Why?
|
Disease Reservoirs | 1 | 2002 | 20 | 0.050 |
Why?
|
Cities | 1 | 2022 | 63 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 404 | 0.050 |
Why?
|
Paralysis | 1 | 2021 | 4 | 0.050 |
Why?
|
Parturition | 1 | 2021 | 24 | 0.050 |
Why?
|
Geography | 1 | 2021 | 96 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2022 | 145 | 0.050 |
Why?
|
Prescription Drugs | 1 | 2021 | 30 | 0.050 |
Why?
|
Reoperation | 1 | 2020 | 24 | 0.050 |
Why?
|
Polypharmacy | 1 | 2021 | 25 | 0.050 |
Why?
|
Risk Management | 1 | 2020 | 9 | 0.050 |
Why?
|
Health Behavior | 1 | 2005 | 537 | 0.050 |
Why?
|
Vasodilator Agents | 1 | 2020 | 56 | 0.050 |
Why?
|
Gestational Age | 1 | 2021 | 190 | 0.050 |
Why?
|
Hospitals, Urban | 2 | 2014 | 39 | 0.050 |
Why?
|
Antibodies, Bacterial | 2 | 2012 | 109 | 0.050 |
Why?
|
Tobacco Use Disorder | 1 | 2003 | 237 | 0.040 |
Why?
|
Emigrants and Immigrants | 1 | 2021 | 137 | 0.040 |
Why?
|
Students | 1 | 2005 | 519 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2022 | 885 | 0.040 |
Why?
|
Health Care Reform | 1 | 2019 | 32 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2003 | 519 | 0.040 |
Why?
|
Group Processes | 1 | 2018 | 21 | 0.040 |
Why?
|
Benchmarking | 1 | 2018 | 29 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2012 | 128 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2018 | 42 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2017 | 62 | 0.040 |
Why?
|
Colonoscopy | 2 | 2012 | 104 | 0.040 |
Why?
|
Mental Health | 1 | 2021 | 303 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2018 | 169 | 0.040 |
Why?
|
Capitation Fee | 1 | 2016 | 3 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2016 | 17 | 0.030 |
Why?
|
Health Expenditures | 1 | 2016 | 32 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2019 | 1130 | 0.030 |
Why?
|
Professional Competence | 1 | 2015 | 40 | 0.030 |
Why?
|
School Health Services | 1 | 2016 | 81 | 0.030 |
Why?
|
Information Dissemination | 1 | 2015 | 59 | 0.030 |
Why?
|
Hospitals, Rural | 1 | 2014 | 21 | 0.030 |
Why?
|
Attitude | 1 | 2015 | 104 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2013 | 44 | 0.030 |
Why?
|
Models, Economic | 1 | 2013 | 20 | 0.030 |
Why?
|
Animals | 2 | 2012 | 15081 | 0.030 |
Why?
|
Bronchitis | 1 | 2013 | 6 | 0.030 |
Why?
|
Emergencies | 1 | 2013 | 24 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 144 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2012 | 68 | 0.030 |
Why?
|
Bile Duct Neoplasms | 1 | 2012 | 3 | 0.030 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2012 | 4 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 4 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 225 | 0.030 |
Why?
|
Patient Readmission | 1 | 2013 | 73 | 0.030 |
Why?
|
Family Relations | 1 | 2012 | 46 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2013 | 210 | 0.020 |
Why?
|
Feces | 1 | 2012 | 111 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2013 | 187 | 0.020 |
Why?
|
Delegation, Professional | 1 | 2010 | 1 | 0.020 |
Why?
|
Nursing Evaluation Research | 1 | 2010 | 12 | 0.020 |
Why?
|
Job Satisfaction | 1 | 2010 | 10 | 0.020 |
Why?
|
Employment | 1 | 2010 | 76 | 0.020 |
Why?
|
Pregnancy, Unplanned | 1 | 2009 | 29 | 0.020 |
Why?
|
Social Support | 1 | 2012 | 394 | 0.020 |
Why?
|
Liver | 1 | 2012 | 479 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2008 | 5 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2009 | 105 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 336 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2008 | 82 | 0.020 |
Why?
|
Drug Utilization Review | 1 | 2007 | 7 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2009 | 168 | 0.020 |
Why?
|
Unsafe Sex | 1 | 2009 | 161 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 448 | 0.020 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2006 | 1 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 6 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2006 | 36 | 0.020 |
Why?
|
Tumor Burden | 1 | 2006 | 77 | 0.020 |
Why?
|
Universities | 1 | 2009 | 442 | 0.020 |
Why?
|
Fasting | 1 | 2005 | 54 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2005 | 68 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2005 | 97 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2006 | 214 | 0.020 |
Why?
|
Hospitals, Maternity | 1 | 2003 | 4 | 0.010 |
Why?
|
Sex Distribution | 1 | 2004 | 215 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 2003 | 11 | 0.010 |
Why?
|
Medical History Taking | 1 | 2003 | 33 | 0.010 |
Why?
|
Attitude to Health | 1 | 2005 | 325 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2003 | 562 | 0.010 |
Why?
|
Health Education | 1 | 2005 | 338 | 0.010 |
Why?
|
Risk-Taking | 1 | 2005 | 451 | 0.010 |
Why?
|